Tucson, AZ & Mountain View, CA – Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce a strategic partnership with Cordance Medical to supply MVT’s microbubble product, MVT-100, for research into the use of microbubbles in combination with Cordance’s NeuroAccess™ technology to open the blood-brain barrier.
Cordance’s NeuroAccess™ device is designed to perform liquid biopsies and enhance drug delivery to the brain. This innovative device uses injectable microbubbles, which, when activated by low-frequency ultrasound, vibrate and reversibly stretch the lining of blood vessels, enabling large molecules to pass in and out of the brain. Currently, no microbubbles are FDA-approved for this specific application.
“Our mission at MVT is to unlock the therapeutic potential of ultrasound,” said Dr. Evan Unger, CEO of MVT. “This partnership is critical to advancing our mission. The lack of FDA-approved microbubbles for opening the blood-brain barrier represents a significant challenge in this field. We are excited to collaborate with Cordance Medical with the goal of gaining approval for our microbubbles, MVT-100, for this groundbreaking use.”
“We are eager to partner with MVT on this groundbreaking endeavor,” said Ryan Dittamore, CEO of Cordance Medical. “The ability to safely and non-invasively open the blood-brain barrier is at the core of our mission to improve outcomes for patients with neurological diseases. This collaboration with MVT and their advanced microbubble technology, MVT-100, represents a significant step forward in our goal to revolutionize drug delivery and enable liquid biopsy in brain diseases, ultimately paving the way for new therapeutic options and better patient care.”
About Microvascular Therapeutics
Microvascular Therapeutics is a clinical-stage biotechnology company based in Tucson, Arizona, and a leader in microbubble technology. MVT’s mission is to develop the next generation of contrast agents for diagnostic ultrasound and to advance the field of ultrasound for the diagnosis and treatment of diseases, including vascular conditions. MVT has developed a new, patented microbubble that serves as a platform for developing agents for molecular imaging and image-guided therapy. For more information, visit www.mvtpharma.com.
About Cordance Medical
Cordance Medical is a medical technology company dedicated to improving patient outcomes in brain diseases through its innovative NeuroAccess platform. The platform’s ability to non-invasively open the blood-brain barrier promises to revolutionize drug delivery and enable liquid biopsy, offering new hope to patients with neurological conditions. For more information, visit www.cordancemedical.com
For more information or media inquiries, please contact:
Company Contact:
Microvascular Therapeutics
Dr. Evan C. Unger, Chairman, BOD
Dr. Emmanuelle Meuillet, COO/CSO
Investor Contact:
Bryan Unger
T: 520.907.3537
Cordance Medical
Ryan Dittamore (CEO, Cordance)
Dr Bhaskar Rhamamurthy (CTO)
Investor Contact:
Ryan Dittamore
Forward-Looking Statement:
This press release contains forward-looking statements that are based on current expectations as of the date of these statements. Results may differ substantially due to risks and uncertainties. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
Comments